Study on the efficacy and safety of butylphthalide in combination with eureklin in the treatment of patients with acute cardioembolic stroke
10.12173/j.issn.1008-049X.202311097
- VernacularTitle:丁苯酞联合尤瑞克林治疗急性心源性脑卒中患者的有效性和安全性研究
- Author:
Nian-Feng GUO
1
;
Fei FEI
;
Jia-Dan LI
Author Information
1. 杭州市第一人民医院药学部(杭州 310000)
- Keywords:
Urinary kallidinogenase;
Butylphthalide;
Acute cardioembolic stroke;
Efficacy;
Safety
- From:
China Pharmacist
2023;26(12):420-427
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of Urinary kallidinogenase(UK)combined with butylphthalide in patients with acute cardioembolic stroke(ACS).Methods A retrospective collection was performed for ACS patients diagnosed and treated in Hangzhou First People's Hospital from May 2022 to April 2023.According to the treatment protocol,ACS patients were divided into UK group and Butylphthalide+UK group.The clinical efficacy,neurological function,serum indexes(Hcy,NT-proBNP and VEGF)and prognosis of the two groups were compared after 2 weeks of treatment.Results A total of 86 ACS patients were included in the study,including 43 in the UK group and 43 in the Butylphthalide+UK group.After treatment,the total effective rate of treatment in the Butylphthalide+UK group was significantly higher than that in the UK group(P<0.05),and there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).In addition,the expression levels of Hcy and NT-proBNP in ACS patients in the Butylphthalide+UK group were significantly lower than those in the UK group(P<0.05),while the expression levels of VEGF were significantly higher than those in the UK group(P<0.05).The NIHSS score and mRS score of ACS patients in the Butylphthalide+UK group were significantly lower than those in the UK group(P<0.05).The rate of collateral circulation establishment in the Butylphthalide+UK group was significantly higher than that in the UK group(P<0.05).Conclusion Butaphthalide combined with UK has significant efficacy and high safety in ACS patients,which may be achieved by regulating the expression levels of serum Hcy,NT-proBNP and VEGF,thereby improving neurological function and promoting the establishment of collateral circulation.
